Patents by Inventor Phillip Monk

Phillip Monk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF INHALED INTERFERON-BETA TO IMPROVE OUTCOME IN SARS-CoV-2 INFECTED PATIENTS
    Publication number: 20230338475
    Abstract: The present invention relates to use of inhaled interferon-beta for use in preventing or reducing the severity of lower respiratory tract (LRT) illness in a patient infected with a coronavirus capable of causing acute respiratory distress syndrome, e.g. preventing or reducing the severity of LRT illness in COVID-19 patients infected with SARS-CoV-2. Targeting of such treatment to promote recovery based on simple and quick breathlessness scoring is proposed which is applicable in both the home and hospital environments.
    Type: Application
    Filed: July 19, 2021
    Publication date: October 26, 2023
    Applicant: SYNAIRGEN RESEARCH LIMITED
    Inventors: Richard MARSDEN, Phillip MONK, Tom WILKINSON
  • USE OF INHALED INTERFERON-BETA TO TREAT VIRUS-INDUCED EXACERBATIONS IN COPD PATIENTS UNDERGOING TREATMENT WITH A SYSTEMIC CORTICOSTEROID
    Publication number: 20230241177
    Abstract: The present invention provides interferon-beta (IFN-?) for use in the treatment of virus-induced COPD exacerbations in patients treated with a systemic corticosteroid, wherein the IFN-? is administered by inhalation, e.g. by use of a nebuliser.
    Type: Application
    Filed: September 7, 2021
    Publication date: August 3, 2023
    Inventors: Richard MARSDEN, Phillip MONK, Victoria TEAR, Tom WILKINSON
  • Binding members for IgE molecules
    Patent number: 8389704
    Abstract: This invention relates to binding members, especially antibody molecules, for IgE. The binding members are useful for, inter alia, treatment of disorders mediated by IgE including allergies and asthma.
    Type: Grant
    Filed: February 15, 2008
    Date of Patent: March 5, 2013
    Assignee: MedImmune Limited
    Inventors: Duncan Cochrane, Suzanne Cohen, Louise Claire Dobson, Fredick Per-Olof Eriksson, David Phillip Monk, Karin Von-Wachenfeldt
  • BINDING MEMBERS FOR IGE MOLECULES
    Publication number: 20110212084
    Abstract: This invention relates to binding members, especially antibody molecules, for IgE. The binding members are useful for, inter alia, treatment of disorders mediated by IgE including allergies and asthma.
    Type: Application
    Filed: February 15, 2008
    Publication date: September 1, 2011
    Applicants: ASTRAZENECA AB, MEDIMMUNE LIMITED
    Inventors: Duncan Cochrane, Suzanne Cohen, Louise Claire Dobson, Fredick Per-Olof Eriksson, David Phillip Monk, Karin Von-Wachenfeldt
  • BINDING MEMBERS FOR IGE MOLECULES
    Publication number: 20100150904
    Abstract: This invention relates to binding members, especially antibody molecules, for IgE. The binding members are useful for, inter alia, treatment of disorders mediated by IgE including allergies and asthma.
    Type: Application
    Filed: February 15, 2008
    Publication date: June 17, 2010
    Applicant: AstraZeneca AB
    Inventors: Duncan Cochrane, Suzanne Cohen, Louise Claire Dobson, Fredick Per-Olof Eriksson, David Phillip Monk, Karin Von-Wachenfeldt
  • Human antibody molecules for IL-13
    Publication number: 20050065327
    Abstract: Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralise IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis,.fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.
    Type: Application
    Filed: July 15, 2004
    Publication date: March 24, 2005
    Inventors: Phillip Monk, Lutz Jermutus, Celia Shorrock, Ralph Minter